Acknowledgement

This activity is provided by Talem Health and RME Collaborative.

This online program is recorded content from the live session at Oncology Nursing Conference Fall 2024 and is co-supported by independent medical education grants from Astellas; Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc.; and Regeneron Pharmaceuticals, Inc. This activity is supported by an independent medical education grant from Astellas.

Credit Available

• Nurses — 1.0 Contact Hour (0.75 contact hour of pharmacotherapy credit)

Target Audience

This activity is designed specifically for nurse practitioners, nurses, and other nursing professionals who provide cancer care to patients from rural and underserved communities. 

Program Overview

Oncology nurses in rural and underserved communities play a crucial role in management of gastric cancer, often serving as the primary point of contact for patients navigating complex treatment plans. It is therefore vital that they remain well-versed on the latest advances in the field and feel prepared to employ optimal monitoring and management strategies. To assist oncology nurses in this task, this online, on-demand CE activity will provide an overview of current and emerging systemic therapies for gastric and gastroesophageal junction (GEJ) cancers—including targeted agents and immunotherapy—and the important role of genetic and molecular biomarkers in prognosis and treatment selection. Specialized strategies for identifying and mitigating potential adverse events will also be discussed. 

This enduring activity is a recorded session from Oncology Nursing Conference that took place on December 7, 2024. 

Learning Objectives

Upon completion of this activity, participants should be better able to:  

• Explain the role of biomarkers in gastric/GEJ cancers to guide diagnosis and treatment decisions 
• Describe the mechanism of action of emerging systemic therapies for unresectable locally advanced or metastatic gastric/GEJ cancers 
• Evaluate clinical evidence on the safety and efficacy of current and emerging systemic therapies for locally advanced unresectable or metastatic gastric/GEJ cancers
• Implement team-based strategies for monitoring and managing adverse events associated with systemic therapies for locally advanced unresectable or metastatic gastric/GEJ cancers

Faculty

Nina N. Grenon, DNP, AOCN 
Nurse Practitioner 
Gastrointestinal Oncology 
Dana-Farber Cancer Institute 
Center for Gastrointestinal Oncology 
Boston, MA

 

Lance F. Ortega, MBA, BSN, RN, OCN 
Executive Director, Clinical Operations  
Texas Oncology 
Dallas-Fort Worth, TX 

Joint Accreditation Statement

In support of improving patient care, Talem Health is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.


 

Credit Designation Statement

Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hour. Designated for 0.75 contact hour of pharmacotherapy credit for Advanced Practice Registered Nurses.

Disclosure of Conflicts of Interest

Talem Health adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers, or others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All identified conflicts of interest are thoroughly vetted and mitigated according to Talem Health policy. Talem Health is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company. 

All relevant financial relationships have been mitigated.

The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity: 

Faculty

Nina N. Grenon, DNP, AOCN, has disclosed the following relevant financial relationships: consultant/advisory board member for Astellas.
 
Lance F. Ortega, MBA, BSN, RN, OCN, has no relevant financial relationships to disclose. 

Planners, Managers, and Reviewer 
The Talem Health planners, managers, and reviewer have nothing to disclose. 

Instructions for Participation and Credit

This activity is offered at no cost to participants. To receive CME credit, participants must: 

1. Read the CME/CE information, including learning objectives and disclosure statements. 
2. Complete the pre-test. 
3. View the online activity. 
4. Complete the post-test and evaluation form. 

A post-test score of 75% or higher is required to obtain credit. Your certificate will be made available for immediate download. 

Course Viewing Requirements 

Supported Browsers: 

Desktop/laptop: Newest and last prior version of Google Chrome, Firefox, Safari, and Microsoft Edge
Mobile devices: Newest and last prior version of Safari and Google Chrome

Supported Phones & Tablets: 
All devices

Disclosure of Unlabeled Use 

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.  

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.  

©RME Collaborative, a division of Talem Health, LLC. All Rights Reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Talem Health, LLC is prohibited. 

Media 

Internet activity 

Fee Information 

There is no fee for this educational activity. 

Contact Information 

For questions about this activity, please contact RME Collaborative (a division of Talem Health) at 800-913-9370 or cme@cmeruralhealth.com.